Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis

Abstract

Gastric cancer (GC) is a malignant tumour with high lethality. Accruing evidence elucidates the critical adjusting role of long non-coding RNA (lncRNAs) in human cancers. DDX11 antisense RNA 1 (DDX11-AS1) was previously found to be involved in GC pathogenesis. However, the precise molecular mechanisms of DDX11-AS1 need to be further investigated. In this study, we found that DDX11-AS1 expression was up-regulated in GC tumour tissues and cells. Increased DDX11-AS1 expression was associated with advanced TNM stage and lymph node metastasis. Functionally, knockdown of DDX11-AS1 repressed cell proliferation and clone formation, while induced cell cycle arrest and apoptosis. As expected, DDX11-AS1 overexpression displayed the opposite effect. Mechanically, DDX11-AS1 enhanced SPC18 expression through acting as a ceRNA for miR-873-5p. Furthermore, the inhibitory effect of DDX11-AS1 silencing on malignant biological behaviour of GC cells was attenuated by either miR-873-5p inhibitor or SEC11A up-regulation. Moreover, suppression of DDX11-AS1 also decreased GC tumorigenesis in vivo. In conclusion, DDX11-AS1 may serve as an oncogene in GC progression by sponging miR-873-5p and promoting SPC18 expression, providing a new insight into the mechanisms of DDX11-AS1 and elucidating a promising therapy target in GC.

Inhibition of circRNA circVPS33B Reduces Warburg Effect and Tumor Growth Through Regulating the miR-873-5p/HNRNPK Axis in Infiltrative Gastric Cancer

“…22 Furthermore, lncRNA TDRG1 and lncRNA DDX11-AS1 accelerated the aggressiveness of GC by sponging miR-873-5p. 24,25 Herein, miR-873-5p was lowly expressed in infiltrative GC tissues.…”

“… 23 In addition, miR-873-5p acts as a tumor-inhibiting molecular in GC. 24 , 25 However, the regulatory mechanism of miR-873-5p in GC growth pattern is unclear.…”

Inhibition of circRNA circVPS33B reduces cell malignant behaviors and Warburg effect through regulation of the miR-873-5p/HNRNPK axis in infiltrative gastric cancer 

“…Another research disclosed that miR-873-5p reduced cell invasion and migration through targeting CXCL16 in papillary thyroid cancer [18]. In GC, miR-873-5p expression could be inhibited by lncRNA TDRG1 or lncRNA DDX11-AS1, thereby accelerating the aggressiveness of GC [20,21]. Herein, miR-873-5p expression had a negative correlation with circVPS33B in in ltrative GC tissues.…”

“…Studies have shown that miR-873-5p played an inhibitory role in numerous cancers development, such as glioma [17], papillary thyroid cancer [18], and colorectal cancer [19]. Moreover, miR-873-5p was uncovered to curb the malignancy of GC cells [20,21]. However, the mechanism of miR-873-5p in in ltrative GC progression has not been fully clari ed.…”

<p>LncRNA CTBP1-AS2 Facilitates Gastric Cancer Progression via Regulating the miR-139-3p/MMP11 Axis</p>

“…[21][22][23] For example, the expression of lncRNA DDX11-AS1 is up-regulated in GC tissues, and functionally, DDX11-AS1 facilitates GC progression by inhibiting miR-873-5p expression. 24 LncRNA FTX expression in GC is also up-regulated, and FTX can promote GC proliferation and invasion by adsorbing miR-144 and up-regulating ZFX; 25 conversely, as a tumor suppressor, lncRNA HAND2-AS1 inhibits the proliferation and migration of GC cells through modulating miR-590-3p/KCNT2 axis. 26 In this study, we verified that CTBP1-AS2 was a molecular sponge for miR-139-3p.…”